Forbion Capital

Forbion Capital is one of the largest dedicated European biopharma investors, and the firm’s Munich office is the operational center for its growth-stage activity in continental Europe. The headline number that distinguishes Forbion from most other European biotech firms is the size of its Growth Opportunities Fund, which deploys roughly six hundred million euros into late-stage European biopharma assets. That scale, combined with a focus that is genuinely concentrated in pharma and therapeutics, biotech, and rare and genetic disorders, places Forbion in a small group of European investors capable of leading the kind of nine-figure rounds that late-stage therapeutics companies require to bridge to clinical readout, partnership, or public market. For healthcare AI founders, the relevant question is whether the company’s underlying value driver is genuinely therapeutic, because Forbion is built for that case and not for adjacent ones.

The investment thesis is therapeutic-first. Forbion engages with assets where the value creation logic is anchored in clinical data, regulatory progress, and ultimately commercial or partnership outcomes for a drug, biologic, or rare-disease therapy. AI is integrated into the firm’s worldview as a tool that increasingly underpins drug discovery, target identification, and translational science, but the fund is not built to back a software-only AI platform that lacks a therapeutic asset or pipeline. Stage focus runs from Series B through Series C and into growth and crossover rounds, which means Forbion typically engages with companies that already have meaningful clinical evidence, a defined regulatory path, and an asset story that can absorb significant capital. The Growth Opportunities Fund extends this capacity into the largest late-stage European rounds, frequently as the European anchor in syndicates that include US crossover and growth-stage biotech specialists.

The specific portfolio detail provided in the source is limited, but Forbion has historically been a recognized backer of European biopharma assets across oncology, immunology, rare disease, and platform therapeutics, with a track record that includes both private exits and public-market outcomes. Founders evaluating fit should diligence the current and recent portfolio directly to understand which therapeutic categories and modalities the firm is currently most active in, as biotech investment focus rotates with scientific cycle and regulatory environment.

Check sizes are at the top of the European range, with twenty-five million dollars described as a floor and growth-fund commitments frequently running well into nine figures. The fund leads or co-leads at Series B and beyond and takes meaningful board roles. Geographic focus is European, with the Munich office anchoring continental Europe and broader coverage including the Netherlands and the United Kingdom. There is no published hard revenue requirement, which is appropriate for therapeutics where revenue typically arrives only after regulatory approval; the relevant diligence currency is clinical data, regulatory positioning, and platform validation rather than ARR or commercial traction. For founders running a Series B or later therapeutics round in Europe, Forbion is one of a small handful of credible local lead options.

The firm is partner-driven with deep biopharma experience across the team, and decision-making at the size of the Growth Opportunities Fund involves rigorous investment committee review. Founders should expect comprehensive scientific and clinical diligence, structured engagement with the firm’s clinical and regulatory advisors, and a multi-meeting cycle before a term sheet. Post-investment engagement is typically heavy, with active board participation and structured introductions to downstream US growth investors, public-market crossover funds, and pharma business development teams.

Warm introductions through existing Forbion portfolio CEOs and other top-tier European biotech investors are the most reliable path in. US biotech crossover funds and growth-stage specialists who frequently co-invest with Forbion are also productive referral sources. Pharma business development executives and senior academic founders affiliated with leading European research institutions can provide credible introductions where the scientific basis of the company is the dominant narrative. Cold inbound is read but converts at low rates without a specific scientific or clinical angle that maps directly to the firm’s current focus.

Founders should approach Forbion when the company is genuinely therapeutic, when the round is at Series B or later, when there is meaningful clinical evidence or a credible near-term clinical milestone, and when the capital need fits the firm’s growth-fund scale. Forbion is not the right fit for pure software AI, digital health, diagnostics without a therapeutic angle, or early-stage Series A therapeutics that have not yet generated clinical evidence. For the right late-stage European biopharma founder, Forbion is one of the most consequential local partners available, with the capital base and clinical depth to lead the kind of round that bridges a therapeutic asset to its defining commercial moment.